Page 42 - Aet News Today

While there will never be a perfect solution to preventing drug diversion 100% of the time, leveraging the right people, processes and technology is our best chance of keeping patients safe.

Zocdoc Founder and CEO Oliver Kharraz gave five predictions about how patient preferences will evolve in 2024. Some of them include Americans increasingly seeking cash-pay care options and an uptick in patients seeking mental health appointments before and after the presidential election.

Talkspace is offering free self-guided mental health content to some female Evernow customers over the age of 40, while Evernow is offering discounted menopause care to Talkspace patients.

The integration of AI into cardiology workflows can help triage care automatically, ensuring the right physicians weigh in on patient data at the right time which may potentially improve clinical outcomes for all patients in need.

Sanofi, which markets the two primary treatments for Pompe disease, was trying to add a third one by licensing rights to a Maze Therapeutics drug candidate with a different therapeutic approach. A Federal Trade Commission complaint alleges the deal amounts to a monopoly player taking out its competition.

Integrations are incredibly destabilizing and stressful for impacted employees, as well as for those who “survive.” Organizations that are worth acquiring are successful and attractive because they are comprised of smart, talented people who have created that success.

In the last episode of the year, Wrobel, CEO of an Indiana-based federally qualified health center, describes how a survey helped her and her community workers understand exactly how confident her patients are in managing their own care and the best way to help them with the ultimate goal of improving overall health equity.

Deloitte released a report predicting the key trends that will shape the healthcare landscape in 2024. Some of them include hospital M&A, health systems outsourcing departments and the increasing adoption of generative AI tools.

Pfizer already reported its experimental drug for hemophilia A and B met a pivotal study’s goals of reducing bleeding episodes. During the annual meeting of the American Society of Hematology, the company presented a full look at the results, which are expected to support regulatory submissions soon.

The future of clinical research is a connected user experience with automated workflows, streamlined document exchange and transparency to accelerate studies without compromising compliance.